Transforming MIBC Treatment: Insights from the NIAGARA TrialPosted on February 16, 2025The landscape of treating muscle-invasive bladder cancer (MIBC) has…
Browsing: #ClinicalTrials
In the evolving landscape of cancer careIn the evolving landscape of cancer care, the use of circulating tumor DNA (ctDNA),…
In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the…
On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for…
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer TreatmentThe results of the Phase 3 EMBER-3 trial were unveiled at the…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
IntroductionASCO 2024 Head & Neck Cancer developments brought forth several groundbreaking studies in the field of head and neck cancer,…